Literature DB >> 29428002

Physician Perceptions Regarding Antimicrobial Use in End-of-Life Care.

Christopher E Gaw1, Keith W Hamilton2, Jeffrey S Gerber3, Julia E Szymczak4.   

Abstract

BACKGROUND The decision to utilize antimicrobials in end-of-life situations is complex. Understanding the reasons why physicians prescribe antimicrobials in this patient population is important for informing the design of antimicrobial stewardship interventions. METHODS A 51-item survey containing both closed and open-ended questions on end-of-life antimicrobial use was administered to physicians affiliated with the University of Pennsylvania and Children's Hospital of Philadelphia from January through April 2017. A mixed-methods approach was used to analyze responses. RESULTS Of 637 physicians surveyed, 283 responses (44.4%) were received. Most (86.2%) physicians believed that respecting a patient's wish to continue antimicrobials was important. Approximately half of physicians (49.8%) believed that antimicrobial use at the end of life contributes to resistance. A higher proportion of pediatricians would often or always continue antimicrobial treatment for active infections and for hospice patients whose death was imminent compared to adult physicians (P<.001). Analysis of free-text responses revealed additional reasons why physicians may continue antimicrobials at end of life, including meeting family expectations, wanting to avoid the perception of "giving up," uncertainty about prognosis, and reducing patient pain or discomfort. CONCLUSIONS Physician decision making concerning antimicrobial use in patients at the end of life is multifactorial. Clinicians may overweigh the benefits of antimicrobial therapy in end-of-life situations and view the importance of adhering to stewardship policies differently. Pediatric and adult clinicians have different approaches to this patient population. Better understanding of the complex decision making that occurs in the end-of-life patient population can help guide antimicrobial stewardship policies and improve patient care. Infect Control Hosp Epidemiol 2018;39:383-390.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29428002     DOI: 10.1017/ice.2018.6

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Perspectives on antimicrobial use at the end of life among antibiotic stewardship programs: A survey of the Society for Healthcare Epidemiology of America Research Network.

Authors:  Rupak Datta; Jeffrey Topal; Dayna McManus; Louise-Marie Dembry; Vincent Quagliarello; Manisha Juthani-Mehta
Journal:  Infect Control Hosp Epidemiol       Date:  2019-07-22       Impact factor: 3.254

2.  Antibiotic stewardship program (ASP) in palliative care: antibiotics, to give or not to give.

Authors:  Kai Chee Hung; Lai Wei Lee; Yi Xin Liew; Lalit Krishna; Maciej Piotr Chlebicki; Shimin Jasmine Chung; Andrea Lay-Hoon Kwa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-20       Impact factor: 3.267

3.  Concordance Between Proxy Level of Care Preference and Advance Directives Among Nursing Home Residents With Advanced Dementia: A Cluster Randomized Clinical Trial.

Authors:  Simon M Cohen; Angelo E Volandes; Michele L Shaffer; Laura C Hanson; Daniel Habtemariam; Susan L Mitchell
Journal:  J Pain Symptom Manage       Date:  2018-09-29       Impact factor: 3.612

4.  Increased Length of Stay Associated With Antibiotic Use in Older Adults With Advanced Cancer Transitioned to Comfort Measures.

Authors:  Rupak Datta; Mojun Zhu; Ling Han; Heather Allore; Vincent Quagliarello; Manisha Juthani-Mehta
Journal:  Am J Hosp Palliat Care       Date:  2019-06-11       Impact factor: 2.500

5.  Why we prescribe antibiotics for too long in the hospital setting: a systematic scoping review.

Authors:  Robin M E Janssen; Anke J M Oerlemans; Johannes G Van Der Hoeven; Jaap Ten Oever; Jeroen A Schouten; Marlies E J L Hulscher
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.